BioCentury | Sep 22, 2014
Clinical News

CTP-730: Phase I started

...I trial to evaluate single doses of 5, 10, 20, 30 and 40 mg oral CTP-730...
...partnered to develop deuterium-modified compounds for cancer and inflammation. The deal is initially focusing on CTP-730...
...up to 4 programs. Concert granted Celgene an exclusive, worldwide license to develop and commercialize CTP-730...
Items per page:
1 - 1 of 1